Intravenous immunoglobulin for infectious diseases: Back to the pre-antibiotic and passive prophylaxis era?

Jagadeesh Bayry, Sébastien Lacroix-Desmazes, Michel D. Kazatchkine, Srini V. Kaveri

Tutkimustuotos: Article

71 Sitaatiot (Scopus)

Abstrakti

The dramatic increase in both the number of novel infectious agents and resistance to antimicrobial drugs has incited the need for adjunct therapies in the war against infectious diseases. Exciting recent studies have demonstrated the use of antibodies in the form of intravenous immunoglobulin (IVIg) against infections. By virtue of the diverse repertoire of immunoglobulins that possess a wide spectrum of antibacterial and antiviral specificities, IVIg provides antimicrobial efficacy independently of pathogen resistance and represents a promising alternative strategy for the treatment of diseases for which a specific therapy is not yet available.
AlkuperäiskieliEnglish
JulkaisuTrends in Pharmacological Sciences
Vuosikerta25
Numero6
DOI - pysyväislinkit
TilaPublished - 1 tammikuuta 2004

Sormenjälki Sukella tutkimusaiheisiin 'Intravenous immunoglobulin for infectious diseases: Back to the pre-antibiotic and passive prophylaxis era?'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.

  • Siteeraa tätä